Unlock Premium for Just $9.99/Month – Special Launch Offer, Limited Time Only
Get Premium
VTVT vTv Therapeutics Inc
- Stocks
- Healthcare
- NASDAQ: VTVT
Price (delayed)
$17.01
Market cap
$54.34M
P/E Ratio
N/A
Dividend/share
N/A
EPS
-$2.96
Enterprise value
$23.41M
vTv Therapeutics Inc. is a clinical-stage biopharmaceutical company focused on developing oral, small molecule drug candidates. vTv has a pipeline of clinical drug candidates led by programs for the treatment
Highlights
The company's EPS has surged by 66% YoY and by 8% QoQ
VTVT's debt has dropped by 58% year-on-year and by 26% since the previous quarter
vTv Therapeutics's revenue has plunged by 98% from the previous quarter and by 98% YoY
vTv Therapeutics's gross profit has plunged by 98% from the previous quarter and by 98% YoY
Key stats
What are the main financial stats of VTVT
Market
Valuations
Earnings
Shares outstanding
3.19M
Market cap
$54.34M
Enterprise value
$23.41M
Price to earnings (P/E)
N/A
Price to book (P/B)
6.85
Price to sales (P/S)
3,191.48
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
1,376.8
Revenue
$17,000
Gross profit
$17,000
Operating income
-$24.69M
Net income
-$18.69M
EBIT
-$18.69M
EBITDA
-$18.61M
Free cash flow
-$23.66M
Per share
Balance sheet
Liquidity
EPS
-$2.96
EPS diluted
-$2.96
Free cash flow per share
-$7.42
Book value per share
$2.48
Revenue per share
$0.01
TBVPS
$10.04
Total assets
$32.03M
Total liabilities
$23.13M
Debt
$125,000
Equity
$7.92M
Working capital
$27.6M
Debt to equity
0.02
Current ratio
7.39
Quick ratio
7.2
Net debt/EBITDA
1.66
Margins
Efficiency
Dividend
EBITDA margin
-109,488.2%
Gross margin
100%
Net margin
-109,935.3%
Operating margin
-145,205.9%
Return on assets
-46.7%
Return on equity
-144.9%
Return on invested capital
N/A
Return on capital employed
-67.4%
Return on sales
-109,935.3%
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A
VTVT stock price
How has the vTv Therapeutics stock price performed over time
Intraday
-2.8%
1 week
12.87%
1 month
2.84%
1 year
-16.98%
YTD
23.18%
QTD
13.4%
Financial performance
How have vTv Therapeutics's revenue and profit performed over time
Revenue
$17,000
Gross profit
$17,000
Operating income
-$24.69M
Net income
-$18.69M
Gross margin
100%
Net margin
-109,935.3%
vTv Therapeutics's revenue has plunged by 98% from the previous quarter and by 98% YoY
vTv Therapeutics's gross profit has plunged by 98% from the previous quarter and by 98% YoY
The net income is up by 9% year-on-year
VTVT's operating income is down by 5% YoY and by 2.1% QoQ
Price vs fundamentals
How does VTVT's price correlate with its fundamentals
Growth
What is vTv Therapeutics's growth rate over time
Valuation
What is vTv Therapeutics stock price valuation
P/E
N/A
P/B
6.85
P/S
3,191.48
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
1,376.8
The company's EPS has surged by 66% YoY and by 8% QoQ
VTVT's price to book (P/B) is 67% higher than its last 4 quarters average of 4.1
VTVT's equity has dropped by 62% year-on-year and by 35% since the previous quarter
The P/S is 103% higher than the 5-year quarterly average of 1568.9
vTv Therapeutics's revenue has plunged by 98% from the previous quarter and by 98% YoY
Efficiency
How efficient is vTv Therapeutics business performance
vTv Therapeutics's return on assets has increased by 42% YoY but it has decreased by 15% QoQ
vTv Therapeutics's return on equity has decreased by 27% QoQ
Dividends
What is VTVT's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A
There are no recent dividends present for VTVT.
Financial health
How did vTv Therapeutics financials performed over time
VTVT's total assets is 38% greater than its total liabilities
VTVT's total assets is down by 41% year-on-year and by 16% since the previous quarter
The current ratio is up by 22% year-on-year
VTVT's debt is 98% smaller than its equity
The debt to equity has soared by 100% since the previous quarter and by 100% year-on-year
VTVT's equity has dropped by 62% year-on-year and by 35% since the previous quarter
All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.